Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of triglyceride-lowering drugs. He has worked with a variety of several novel triglyceride-lowering compounds, including niacin and novel niacin mimetics, fibrates and novel fibrates, novel fish oils, and a host of other emerging drugs: DGAT-1 inhibitor, MTP inhibitor, AngPTL3 inhibitor, ApoC3 inhibitor, a glitazar, and perhaps most uniquely, lipoprotein lipase gene replacement therapy. He also employs a variety of provoked outcomes in his research, such as oral fat tolerance testing with/without radiolabeled fat to trace chylomicrons, stable isotope lipoprotein kinetics, euglycemic-hyperinsulinemic clamp, FSIVGTT, indocyanine green to test hepatic function, other nutrient challenges, and a variety of modalities to measure niacin-associated skin toxicity. A common theme of these is the concept that perturbing a system reveals more as an outcome than the steady state. His research focuses on translating pre-clinical findings into humans, and indeed works exclusively on patient-oriented, clinical research.
Dr. Dunbar specializes in the treatment of cholesterol disorders, and practices in the Preventive Cardiology Clinic at the Pereleman Center for Advanced Medicine
Cuchel M, Raper AC, Pryma DA, Freifelder RH, Poria R, Cromley D, Li X, Dunbar RL, French B, Qu L, Farver W, Su C-C, Lund-Katz S, Baer A, Ruotolo G, Akerblad P, Ryan CS, Xiao L, Kirchgessner TG, Millar JS, Billheimer JT, Rader DJ : A Novel Approach to Measuring Macrophage-specific Reverse Cholesterol Transport in Vivo in Humans. J Lipid Res February 2017 Notes: Published Online Ahead of Print 2/2017.
Ueda M*, Dunbar RL*, Wolska A, Sikora TU, del Rosario Escobar M, Seliktar N, deGoma E, DerOhannessian S, Morrell L, McIntyre AD, Burke F, Sviridov D, Amar M, Shamburek RD, Freeman L, Hegele RA, Remaley AT, Rader DJ: A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency with Severe Triglyceridemia and Pancreatitis. J Clin Endocrinol Metab 102, February 2017 Notes: [Co-First Author, Accepted for Publication on 1/2017]
Dunbar RL*, Goel H*, Tuteja S, Song W-L,
Nathanson G, Babar Z, Lalic D, Gelfand JM, Rader DJ, Grove GL: Measuring Physical Stigmata of Niacin-Associated Skin Toxicity by Colorimetry, White-Light Spectroscopy, Laser Doppler Flowmetry, and Thermometry in Combination with Symptom Perception Scoring: Methods to Aid Development of Niacin Mimetics. J Lipid Res January 2017 Notes: Co-First Authors, Published Online Ahead of Print 1/2017.
Dewey FE*, Gusarova V*, Dunbar RL*, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV , Bruse S, Dansky HM , Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH , Lee I-T, Liang K-W, Guo X, Rotter JI, Chen Y-D I on behalf of the TAICHI consortium, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ on behalf of the Geisinger-Regeneron DiscovEHR Collaboration, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A : Genetic and Pharmacologic Inactivation of ANGPTL3 and Atherosclerotic Cardiovascular Disease. NEJM 2017 Notes: [*Co-First Authors, Provisionally Accepted]
Dunbar RL, Bouzelmat A, Gipe DA, Pordy R, Sasiela W, Mellis S, Banerjee P : Inhibition Of ANGPTL3 By Evinacumab Reduced Triglycerides (TGs) And LDL-C In Subjects Presenting With Modest Elevations In TGs And/or LDL-C, Recapitulating The Hypolipidemic Effects Of Loss-of-function (LoF) Mutations Of ANGPTL3. Circulation Novemeber 2016 Notes: [Oral Presentation to the American Heart Association Scientific Sessions 2016, New Orleans, LA]
Digenio A*, Dunbar RL*, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care 39(8): 1408-1415, August 2016 Notes: [Co-first author]
Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE: Effects of Extended Release Niacin added to Simvastatin/Ezetemibe on Glucose and Insulin values in AIM HIGH American Journal of Medicine 129(7), July 2016.
Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Lipidology 10(3), May 2016 Notes: [Won Second Place in National Abstract Competition and Accepted as Oral Presentation to the 2016 National Lipid Association Scientific Sessions, New Orleans, May 19-22, 2016]
Goel H, Dunbar RL: Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics. Curr Atheroscler Rep 18(4): 17, April 2016.
Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan JS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN : Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. Arterioscler Thromb Vasc Biol 36, March 2016.
back to top
Last updated: 02/20/2017
The Trustees of the University of Pennsylvania